Ketamine and depression: a narrative review

References

• World Health Organization. Depression; 2018 Available from: https://www.who.int/news-room/fact-sheets/detail/depression. Accessed 66, 2019
   Google Scholar
• Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). J Affect Disord. 2013;151:59–65. doi:10.1016/j.jad.2013.08.00223790554
   PubMed Web of Science ®Google Scholar
• Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475:27–30. doi:10.1038/475027a21734685
   PubMed Web of Science ®Google Scholar
• Vandeleur CL, Fassassi S, Castelao E, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. Psychiatry Res. 2017;250:50–58. doi:10.1016/j.psychres.2017.01.06028142066
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–251. doi:10.1001/archgenpsychiatry.2011.1221383262
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–537. doi:10.1001/archpsyc.59.6.53012044195
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003;5:417–418. doi:10.1007/s11920-003-0077-214609495
   PubMedGoogle Scholar
• Rong C, Park C, Rosenblat J, et al. Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder. Int J Environ Res Public Health. 2018;15:771. doi:10.3390/ijerph15061188
   PubMed Web of Science ®Google Scholar
• Duman RS. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597–606. doi:10.1001/archpsyc.1997.018301900150029236543
   PubMed Web of Science ®Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185:1–10. doi:10.1016/0014-2999(90)90204-J2171955
   PubMed Web of Science ®Google Scholar
• Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30:563–569. doi:10.1016/j.tips.2009.09.00219837463
   PubMed Web of Science ®Google Scholar
• Skolnick P, Layer R, Popik P, Nowak G, Paul I, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 1996;29:23–26. doi:10.1055/s-2007-9795378852530
   PubMed Web of Science ®Google Scholar
• Lener MS, Niciu MJ, Ballard ED, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81:886–897. doi:10.1016/j.biopsych.2016.05.00527449797
   PubMed Web of Science ®Google Scholar
• Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signaling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16:472–486. doi:10.1038/nrd.2017.1628303025
   PubMed Web of Science ®Google Scholar
• Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663–665. doi:10.1176/appi.ajp.159.4.66311925309
   PubMed Web of Science ®Google Scholar
• Grimm S, Luborzewski A, Schubert F, et al. Region-specific glutamate changes in patients with unipolar depression. J Psychiatr Res. 2012;46:1059–1065. doi:10.1016/j.jpsychires.2012.04.01822595871
   PubMed Web of Science ®Google Scholar
• Deutschenbaur L, Beck J, Kiyhankhadiv A, et al. Role of calcium, glutamate and NMDA in major depression and therapeutic application. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:325–333. doi:10.1016/j.pnpbp.2015.02.01525747801
   PubMed Web of Science ®Google Scholar
• Ignácio ZM, Réus GZ, Arent CO, Abelaira HM, Pitcher MR, Quevedo J. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs: mTOR and depression. Br J Clin Pharmacol. 2016;82:1280–1290. doi:10.1111/bcp.1297526613210
   PubMed Web of Science ®Google Scholar
• Duman RS. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety. 2014;31:291–296. doi:10.1002/da.2014.31.issue-424616149
   PubMed Web of Science ®Google Scholar
• Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992;260:1209–1213.1312163
   PubMed Web of Science ®Google Scholar
• Miller OH, Yang L, Wang C-C, et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife. 2014;3:e03581. doi:10.7554/eLife.0358125340958
   PubMed Web of Science ®Google Scholar
• White PF, Ham J, Way WL, Trevor AJ. Pharmacology of ketamine isomers in surgical patients. Anesthesiology. 1980;52:231–239. doi:10.1097/00000542-198003000-000086989292
   PubMed Web of Science ®Google Scholar
• Yeung LY, Wai MSM, Fan M, et al. Hyperphosphorylated tau in the brains of mice and monkeys with long-term administration of ketamine. Toxicol Lett. 2010;193:189–193. doi:10.1016/j.toxlet.2010.01.00820093173
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979;134:382–389. doi:10.1192/bjp.134.4.382
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi:10.1136/jnnp.23.1.5614399272
   PubMed Web of Science ®Google Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–296. doi:10.1111/j.2044-8260.1967.tb00530.x6080235
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi:10.1001/archpsyc.1961.0171012003100413688369
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Fujita A, Harai H, Yoshimura R, Kitamura T, Takahashi K. Definitions of recovery and outcomes of major depression: results from a 10-year follow-up. Acta Psychiatr Scand. 2008;117:35–40.17986318
   PubMed Web of Science ®Google Scholar
• Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67:1428–1434. doi:10.4088/JCP.v67n091417017830
   PubMed Web of Science ®Google Scholar
• McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD011611.pub2
   Web of Science ®Google Scholar
• Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD011612.pub2
   Web of Science ®Google Scholar
• Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin. 2017;33:701–711. doi:10.1080/03007995.2017.130190328035869
   PubMed Web of Science ®Google Scholar
• Romeo B, Choucha W, Fossati P, Rotge J-Y. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res. 2015;230:682–688. doi:10.1016/j.psychres.2015.08.02926548981
   PubMed Web of Science ®Google Scholar
• Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol. 2014;4:75–99. doi:10.1177/204512531350773924688759
   PubMedGoogle Scholar
• Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46:1459–1472. doi:10.1017/S003329171600006426867988
   PubMed Web of Science ®Google Scholar
• Xu Y, Hackett M, Carter G, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2016;19:pyv124. doi:10.1093/ijnp/pyv12426578082
   PubMed Web of Science ®Google Scholar
• Lee EE, Della Selva MP, Liu A, Himelhoch S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 2015;37:178–184. doi:10.1016/j.genhosppsych.2015.01.00325698228
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45:693–704. doi:10.1017/S003329171500126925010396
   PubMed Web of Science ®Google Scholar
• Ren L, Deng J, Min S, Peng L, Chen Q. Ketamine in electroconvulsive therapy for depressive disorder: a systematic review and meta-analysis. J Psychiatr Res. 2018;104:144–156. doi:10.1016/j.jpsychires.2018.07.00330077114
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, Chan PY, Yatham LN, Lam RW. Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis. Br J Psychiatry. 2017;210:403–407. doi:10.1192/bjp.bp.116.18999328385704
   PubMed Web of Science ®Google Scholar
• Fond G, Bennabi D, Haffen E, et al. A bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression. Sci Rep. 2016;6. doi:10.1038/srep19847
   Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res. 2015;62:23–30. doi:10.1016/j.jpsychires.2015.01.00325684151
   PubMed Web of Science ®Google Scholar
• Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis: ketamine as an antidepressant. Hum Psychopharmacol Clin Exp. 2015;30:152–163. doi:10.1002/hup.v30.3
   PubMed Web of Science ®Google Scholar
• Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments.. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172:950–966. doi:10.1176/appi.ajp.2015.1501005526423481
   PubMed Web of Science ®Google Scholar
• Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231:3663–3676. doi:10.1007/s00213-014-3664-525038867
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Bentley KH, Eikermann M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516–524. doi:10.1016/j.jad.2018.09.03730286416
   PubMed Web of Science ®Google Scholar
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176:428–438. doi:10.1176/appi.ajp.2019.1902017231109201
   PubMed Web of Science ®Google Scholar
• Arabzadeh S, Hakkikazazi E, Shahmansouri N, et al. Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial. J Affect Disord. 2018;235:236–241. doi:10.1016/j.jad.2018.02.05629660637
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620–630. doi:10.1176/appi.ajp.2018.1706072029656663
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139–148. doi:10.1001/jamapsychiatry.2017.373929282469
   PubMed Web of Science ®Google Scholar
• Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomized, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2018;214:20–26. doi:10.1192/bjp.2018.19630246667
   PubMed Web of Science ®Google Scholar
• Chen M-H, Li C-T, Lin W-C, et al. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: a randomized control study. J Affect Disord. 2018;225:709–714. doi:10.1016/j.jad.2017.09.00828922734
   PubMed Web of Science ®Google Scholar
• Su T-P, Chen M-H, Li C-T, et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482–2492. doi:10.1038/npp.2017.9428492279
   PubMed Web of Science ®Google Scholar
• Hu Y-D, Xiang Y-T, Fang J-X, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46:623–635. doi:10.1017/S003329171500215926478208
   PubMed Web of Science ®Google Scholar
• Li C-T, Chen M-H, Lin W-C, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study: ketamine modulates the PFC. Hum Brain Mapp. 2016;37:1080–1090. doi:10.1002/hbm.2308526821769
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80:424–431. doi:10.1016/j.biopsych.2015.10.01826707087
   PubMed Web of Science ®Google Scholar
• Carspecken CW, Borisovskaya A, Lan ST, et al. Ketamine anesthesia does not improve depression scores in electroconvulsive therapy: a randomized clinical trial. J Neurosurg Anesthesiol. 2018;30:305–313.29847468
   PubMed Web of Science ®Google Scholar
• Gamble JJ, Bi H, Bowen R, et al. Ketamine-based anesthesia improves electroconvulsive therapy outcomes: a randomized-controlled study. Can J Anesth Can Anesth. 2018;65:636–646. doi:10.1007/s12630-018-1088-0
   Google Scholar
• Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–526. doi:10.1016/j.biopsych.2009.04.02919545857
   PubMed Web of Science ®Google Scholar
• Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression: effects of ketamine on suicidality. Depress Anxiety. 2014;31:335–343. doi:10.1002/da.2014.31.issue-424668760
   PubMed Web of Science ®Google Scholar
• Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45:3571–3580. doi:10.1017/S003329171500126926266877
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2015;17:438–443. doi:10.1111/bdi.2015.17.issue-425400146
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized,placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816–826. doi:10.1176/appi.ajp.2016.1601003727056608
   PubMed Web of Science ®Google Scholar
• Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. 2014;215:355–361. doi:10.1016/j.psychres.2013.12.00824374115
   PubMed Web of Science ®Google Scholar
• Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth. 1981;53:805–810. doi:10.1093/bja/53.8.8057272143
   PubMed Web of Science ®Google Scholar
• Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982;71:539–542. doi:10.1002/jps.26007105167097501
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos. 2003;24:37–43. doi:10.1002/(ISSN)1099-081X12516077
   PubMed Web of Science ®Google Scholar
• Lapidus KAB, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970–976. doi:10.1016/j.biopsych.2014.03.02624821196
   PubMed Web of Science ®Google Scholar
• Domino EF, Chodoff P, Corssen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 1965;6:279–291. doi:10.1002/cpt19656327914296024
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007;62:1310–1316. doi:10.1016/j.biopsych.2006.09.03717574216
   PubMed Web of Science ®Google Scholar
• Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA. 2005;102:15653–15658. doi:10.1073/pnas.050790110216230605
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621–660. doi:10.1124/pr.117.01519829945898
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509–523. doi:10.1146/annurev-med-053013-06294625341010
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Yokoyama C, Mizuma H, et al. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Transl Psychiatry. 2014;4:e342. doi:10.1038/tp.2013.11224399045
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Ohba H, Nishiyama S, et al. Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:2666–2674. doi:10.1038/npp.2013.176
   PubMed Web of Science ®Google Scholar
• Pham TH, Mendez-David I, Defaix C, et al. Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice. Neuropharmacology. 2017;112:198–209. doi:10.1016/j.neuropharm.2016.05.01027211253
   PubMed Web of Science ®Google Scholar
• Du Jardin KG, Müller HK, Elfving B, Dale E, Wegener G, Sanchez C. Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: a critical review. Prog Neuropsychopharmacol Biol Psychiatry. 2016;71:27–38. doi:10.1016/j.pnpbp.2016.05.00727262695
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486. doi:10.1038/nature1799827144355
   PubMed Web of Science ®Google Scholar
• Philip NS, Carpenter LL, Tyrka AR, Price LH. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology (Berl). 2010;212:1–12. doi:10.1007/s00213-010-1932-620614106
   PubMed Web of Science ®Google Scholar
• Hustveit O, Maurset A, Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995;77:355–359. doi:10.1111/j.1600-0773.1995.tb01041.x8835358
   PubMedGoogle Scholar
• Lewis AS, Vaidya SP, Blaiss CA, et al. Deletion of the hyperpolarization-activated cyclic nucleotide-gated channel auxiliary subunit TRIP8b impairs hippocampal Ih localization and function and promotes antidepressant behavior in mice. J Neurosci Off J Soc Neurosci. 2011;31:7424–7440. doi:10.1523/JNEUROSCI.0936-11.2011
   PubMed Web of Science ®Google Scholar
• Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205–1215. doi:10.1176/appi.ajp.2018.1802013830153752
   PubMed Web of Science ®Google Scholar
• Zhang K, Hashimoto K. Lack of opioid system in the antidepressant actions of ketamine. Biol Psychiatry. 2019;85:e25–e27. doi:10.1016/j.biopsych.2018.11.00630545521
   PubMed Web of Science ®Google Scholar
• Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry. 2019. doi:10.1001/jamapsychiatry.2018.3990
   Web of Science ®Google Scholar
• Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;313–333. doi:10.1007/978-3-540-74806-9_1518175098
   PubMedGoogle Scholar
• Zhang J-C, Li S-X, Hashimoto KR. (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–141. doi:10.1016/j.pbb.2013.11.03324316345
   PubMed Web of Science ®Google Scholar
• Fukumoto K, Toki H, Iijima M, et al. Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther. 2017;361:9–16. doi:10.1124/jpet.116.23922828115553
   PubMed Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang J-C, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632. doi:10.1038/tp.2015.13626327690
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective. Psychiatry Clin Neurosci. 2019. doi:10.1111/pcn.12902
   Web of Science ®Google Scholar
• Zarate CA, Brutsche N, Laje G, et al. Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72:331–338. doi:10.1016/j.biopsych.2012.03.00422516044
   PubMed Web of Science ®Google Scholar
• Persson J, Hasselström J, Maurset A, et al. Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol. 2002;57:869–875. doi:10.1007/s00228010035311936706
   PubMed Web of Science ®Google Scholar
• Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853–858. doi:10.1124/dmd.30.7.85312065445
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2001;29:887–890.11353758
   PubMed Web of Science ®Google Scholar
• Adams JD, Baillie TA, Trevor AJ, Castagnoli N. Studies on the biotransformation of ketamine. 1-identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom. 1981;8:527–538. doi:10.1002/bms.12000811037317567
   PubMedGoogle Scholar
• Desta Z, Moaddel R, Ogburn ET, et al. Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica. 2012;42:1076–1087. doi:10.3109/00498254.2012.68577722612619
   PubMed Web of Science ®Google Scholar
• Moaddel R, Venkata SL, Tanga MJ, et al. A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome. Talanta. 2010;82:1892–1904. doi:10.1016/j.talanta.2010.06.02320875593
   PubMed Web of Science ®Google Scholar
• Blier P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry. 2012;72:e11–e12. doi:10.1016/j.biopsych.2012.02.03922502989
   PubMed Web of Science ®Google Scholar
• Pickering G, Pereira B, Morel V, et al. Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients. Contemp Clin Trials. 2014;38:314–320. doi:10.1016/j.cct.2014.06.00424948402
   PubMed Web of Science ®Google Scholar
• Husain SS, Kevan IM, Linnell R, Scott AIF. Electroconvulsive therapy in depressive illness that has not responded to drug treatment. J Affect Disord. 2004;83:121–126. doi:10.1016/j.jad.2004.05.00615555704
   PubMed Web of Science ®Google Scholar
• Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS Drugs. 2015;29:181–188. doi:10.1007/s40263-015-0232-425715884
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605–1611. doi:10.4088/JCP.09m05327blu20673547
   PubMed Web of Science ®Google Scholar
• Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–946. doi:10.1016/j.biopsych.2011.12.01022297150
   PubMed Web of Science ®Google Scholar
• Ballard ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015;68:68–73. doi:10.1016/j.jpsychires.2015.06.00326228403
   PubMed Web of Science ®Google Scholar
• Erhardt S, Lim CK, Linderholm KR, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38:743–752. doi:10.1038/npp.2012.248
   PubMed Web of Science ®Google Scholar
• Zhu W, Ding Z, Zhang Y, Shi J, Hashimoto K, Lu L. Risks associated with misuse of ketamine as a rapid-acting antidepressant. Neurosci Bull. 2016;32:557–564. doi:10.1007/s12264-016-0081-227878517
   PubMed Web of Science ®Google Scholar
• Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5:65–78. doi:10.1016/S2215-0366(17)30272-928757132
   PubMed Web of Science ®Google Scholar
• Orhurhu VJ, Claus LE, Cohen SP. Ketamine Toxicity. In StatPearls. StatPearls Publishing; 2019.
   Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793. doi:10.1001/archgenpsychiatry.2010.9020679587
   PubMed Web of Science ®Google Scholar
• Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol Lett. 2013;55(7):287–293.
   Google Scholar
• Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:9. doi:10.1001/archpsyc.63.8.856
   Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354. doi:10.1016/S0006-3223(99)00230-910686270
   PubMed Web of Science ®Google Scholar
• Valentine GW, Mason GF, Gomez R, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res. Neuroimaging. 2011;191:122–127. doi:10.1016/j.pscychresns.2010.10.009
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134–1142. doi:10.1176/appi.ajp.2013.1303039223982301
   PubMed Web of Science ®Google Scholar
• Lai R, Katalinic N, Glue P, et al. Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 2014;15:579–584. doi:10.3109/15622975.2014.92269724910102
   PubMed Web of Science ®Google Scholar
• Järventausta K, Chrapek W, Kampman O, et al. Effects of S-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J Ect. 2013;29:158–161. doi:10.1097/YCT.0b013e318283b7e923475029
   PubMed Web of Science ®Google Scholar
• Yoosefi A, Sepehri AS, Kargar M, et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J Ect. 2014;30:15–21. doi:10.1097/YCT.0b013e3182a4b4c624091902
   PubMed Web of Science ®Google Scholar
• Loo CK, Katalinic N, Garfield JBB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 2012;142:233–240. doi:10.1016/j.jad.2012.04.03222858219
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J Ect. 2012;28:157–161. doi:10.1097/YCT.0b013e31824f829622847373
   PubMed Web of Science ®Google Scholar
• Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J Ect. 2012;28:128–132. doi:10.1097/YCT.0b013e31823fbb1322622291
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol Clin Exp. 2013;28:87–90. doi:10.1002/hup.v28.1
   PubMed Web of Science ®Google Scholar
• Rasmussen KG, Kung S, Lapid MI, et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014;215:362–365. doi:10.1016/j.psychres.2013.12.02724388729
   PubMed Web of Science ®Google Scholar
• Shams Alizadeh N, Maroufi A, Nasseri K, et al. Antidepressant effect of combined ketamine and electroconvulsive therapy on patients with major depressive disorder: a randomized trial. Iran J Psychiatry Behav Sci. 2015;9:e1578. doi:10.17795/ijpbs26576166
   PubMedGoogle Scholar
• Salehi B, Mohammadbeigi A, Kamali A, Taheri-Nejad M, Moshiri I. Impact comparison of ketamine and sodium thiopental on anesthesia during electroconvulsive therapy in major depression patients with drug-resistant; a double-blind randomized clinical trial. Ann Card Anaesth. 2015;18:486–490. doi:10.4103/0971-9784.16644426440233
   PubMedGoogle Scholar
• Ozkan Kuscu O, Karacaer F, Biricik E, Gulec E, Tamam L, Gunes Y. Effect of ketamine, thiopental and ketamine–thiopental combination during electroconvulsive therapy for depression. Turk J Anesth Reanim. 2015;43:313–317. doi:10.5152/TJAR.
   Google Scholar
• Zhong X, He H, Zhang C, et al. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. J Affect Disord. 2016;201:124–130. doi:10.1016/j.jad.2016.05.01127208499
   PubMed Web of Science ®Google Scholar
• Zhang M, Rosenheck R, Lin X, et al. A randomized clinical trial of adjunctive ketamine anesthesia in electro-convulsive therapy for depression. J Affect Disord. 2018;227:372–378. doi:10.1016/j.jad.2017.11.03429149755
   PubMed Web of Science ®Google Scholar
• Ray-Griffith SL, Eads LA, Han X, Golden K, Stowe ZN. A randomized pilot study comparing ketamine and methohexital anesthesia for electroconvulsive therapy in patients with depression. J Ect. 2017;33:268–271. doi:10.1097/YCT.000000000000040628422805
   PubMed Web of Science ®Google Scholar
• Fernie G, Currie J, Perrin JS, et al. Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial. Br J Psychiatry J Ment Sci. 2017;210:422–428. doi:10.1192/bjp.bp.116.189134
   PubMed Web of Science ®Google Scholar
• Chen Q, Min S, Hao X, et al. Effect of low dose of ketamine on learning memory function in patients undergoing electroconvulsive therapy-a randomized, double-blind, controlled clinical study. J Ect. 2017;33:89–95. doi:10.1097/YCT.000000000000040627828927
   PubMed Web of Science ®Google Scholar
• Anderson IM, Blamire A, Branton T, et al. Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. Lancet Psychiatry. 2017;4:365–377. doi:10.1016/S2215-0366(17)30077-928359862
   PubMed Web of Science ®Google Scholar
• Anderson IM, Blamire A, Branton T, et al. Randomised Controlled Trial of Ketamine Augmentation of Electroconvulsive Therapy to Improve Neuropsychological and Clinical Outcomes in Depression (ketamine-ect Study). NIHR Journals Library; 2017.
   Google Scholar
• Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65:289–295. doi:10.1016/j.biopsych.2008.08.01418822408
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71–82. doi:10.1017/S146114570900016919288975
   PubMed Web of Science ®Google Scholar
• Salvadore G, Cornwell BR, Sambataro F, et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology. 2010;35:1415–1422. doi:10.1038/npp.2010.2420393460
   PubMed Web of Science ®Google Scholar
• aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–145. doi:10.1016/j.biopsych.2009.08.03819897179
   PubMed Web of Science ®Google Scholar
• Permoda-Osip A, Adamski R, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Skibinska M, Rybakowski JK. P.2.e.019 Efficacy of single ketamine infusion in bipolar depression: relationship with serum BDNF. Eur Neuropsychopharmacol. 2011;21:S428–S429. doi:10.1016/S0924-977X(11)70692-7
   Web of Science ®Google Scholar
• Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14:1127–1131. doi:10.1017/S146114571100062921557878
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1155–1159. doi:10.1016/j.pnpbp.2011.03.01921466832
   PubMed Web of Science ®Google Scholar
• Thakurta RG, Ray P, Das R, Thakurta R, Kanji D, Bisui B. Rapid antidepressant response with ketamine: is it the solution to resistant depression? Indian J Psychol Med. 2012;34:56–60. doi:10.4103/0253-7176.9616122661809
   PubMedGoogle Scholar
• Salvadore G, van der Veen JW, Zhang Y, et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol. 2012;15:1063–1072. doi:10.1017/S146114571100159322040773
   PubMed Web of Science ®Google Scholar
• Carlson PJ, Diazgranados N, Nugent AC, et al. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry. 2013;73:1213–1221. doi:10.1016/j.biopsych.2013.02.00823540908
   PubMed Web of Science ®Google Scholar
• Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95:114–118. table of contents. doi:10.1097/00000539-200212000-0003112088953
   PubMed Web of Science ®Google Scholar